Growth Metrics

Lisata Therapeutics (LSTA) Depreciation & Amortization (CF) (2016 - 2025)

Lisata Therapeutics filings provide 13 years of Depreciation & Amortization (CF) readings, the most recent being -$31000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) fell 146.27% year-over-year to -$31000.0, compared with a TTM value of $100000.0 through Dec 2025, down 50.0%, and an annual FY2025 reading of $100000.0, down 50.0% over the prior year.
  • Depreciation & Amortization (CF) hit -$31000.0 in Q4 2025 for Lisata Therapeutics, down from $44000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $67000.0 in Q4 2024, with the low at -$31000.0 in Q4 2025.
  • Median Depreciation & Amortization (CF) over the past 3 years was $45500.0 (2024), compared with a mean of $40750.0.
  • The sharpest move saw Depreciation & Amortization (CF) surged 42.55% in 2024, then tumbled 146.27% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $47000.0 in 2023, then skyrocketed by 42.55% to $67000.0 in 2024, then tumbled by 146.27% to -$31000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at -$31000.0, $44000.0, and $44000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.